FDA de­lays re­view of Bio­Mar­in's he­mo­phil­ia gene ther­a­py af­ter da­ta up­date

The FDA has ex­tend­ed its re­view of Bio­Marin’s gene ther­a­py for he­mo­phil­ia A by three months, for­mal­iz­ing an ex­pect­ed de­lay that will now push out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.